Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
CGEN is in the long-term down -79% below S&P in 7 years.
Description: Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company?s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||72.13 M||Cash From Investing Activities||-64.09 M||Cash From Operating Activities||-11.15 M||Gross Profit||130 K|
|Net Profit||-6.14 M||Operating Profit||-6.32 M||Total Assets||108.48 M||Total Current Assets||68.55 M|
|Total Current Liabilities||5.24 M||Total Debt||Total Liabilities||7.52 M||Total Revenue||510 K|
|High 52 week||4.7||Low 52 week||2.35||Last close||3.17||Last change||2.44%|
|RSI||52.4||Average true range||0.22||Beta||0.71||Volume||73.51 K|
|Simple moving average 20 days||0.04%||Simple moving average 50 days||-7.51%||Simple moving average 200 days||-11.85%|
|Performance Week||-7.17%||Performance Month||2.44%||Performance Quart||-12.07%||Performance Half||-5.51%|
|Performance Year||24.14%||Performance Year-to-date||26.62%||Volatility daily||4.42%||Volatility weekly||9.89%|
|Volatility monthly||20.27%||Volatility yearly||70.2%||Relative Volume||296.09%||Average Volume||219.16 K|
|New High||New Low|
2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4
2019-03-07 09:09:02 | Compugen CGEN Upgraded to Strong Buy: What Does It Mean for the Stock?
2019-03-07 09:06:02 | Merrimack MACK Incurs Narrower-Than-Expected Loss in Q4
2019-03-05 07:00:00 | Compugen to Present at the Cowen and Company 39th Annual Health Care Conference
2019-01-16 07:07:39 | How Much Of Compugen Ltd. NASDAQ:CGEN Do Institutions Own?
2018-11-23 08:20:00 | New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-11-07 08:20:01 | Compugen CGEN Reports Q3 Loss
2018-11-07 07:20:19 | Compugen: 3Q Earnings Snapshot
2018-11-07 07:00:00 | Compugen Reports Third Quarter 2018 Results
2018-11-05 05:35:10 | Compugen Ltd. CGEN Sees Hammer Chart Pattern: Time to Buy?
2018-10-12 15:09:27 | Don't Fixate On Market Woes, Just Make Your Trades
2018-10-12 10:25:02 | Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
2018-10-12 09:30:01 | Bristol-Myers Inks Deal and Invests $12 Million in Compugen
2018-10-11 07:32:00 | Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake
2018-10-11 07:00:00 | Bristol-Myers to invest in Compugen, collaborate in clinical trials
2018-09-14 13:27:45 | Should You Have Compugen Ltd’s NASDAQ:CGEN In Your Portfolio?
2018-09-05 07:00:00 | Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
2018-08-01 07:28:24 | Compugen: 2Q Earnings Snapshot
2018-08-01 07:00:00 | Compugen Reports Second Quarter 2018 Results
2018-08-01 06:30:00 | Compugen Ltd. to Host Earnings Call
2018-07-02 09:10:15 | Benzinga Pro's 5 Stocks To Watch Today
2018-07-02 07:05:00 | Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254
2018-06-27 12:38:55 | When Should You Buy Compugen Ltd NASDAQ:CGEN?
2018-06-11 07:00:00 | Compugen Announces the Appointment of New Board Members
2018-05-16 08:53:12 | Market Has Not Yet Noticed Potential in Compugen; Have You?
2018-05-09 07:58:19 | Compugen: 1Q Earnings Snapshot
2018-05-09 07:00:00 | Compugen Reports First Quarter 2018 Results
2018-05-02 19:14:18 | Compugen Ltd NASDAQ:CGEN: Should The Recent Earnings Drop Worry You?
2018-04-03 01:00:28 | [$$] AstraZeneca receives regulatory boost for oncology drugs
2018-04-02 10:04:09 | Benzinga Pro's 5 Stocks To Watch Today
2018-04-02 07:01:32 | Compugen, AstraZeneca unit in cancer drug development deal